Skip to content
PICO Portalanswers from OpenAlex

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

PaperCitations, authors & open-access status

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients is a paper indexed in PICO Portal from OpenAlex.

How many citations does Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients have?

PICO Portalcitation count

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients has 84 citations in the OpenAlex counts PICO Portal stores.

When was Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients published?

PICO Portalyear

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients has 2019 year in the PICO Portal index.

What is the open-access status of Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients?

PICO Portaloa status

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients has green oa status in the PICO Portal index.

What is the DOI of Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients?

PICO Portaldoi

The DOI for Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients is on the source record.

What is the PMID of Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients?

PICO Portalpmid

The PMID for Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients is on the source record.

What is the OpenAlex record for Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients?

PICO Portalopenalex

The OpenAlex for Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial